Peptides by condition · Cancer

Peptides studied for cancer

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 9 study pages on cancer: 4 in people (1 of them a meta-analysis or randomized trial), and 3 in animals and 2 in cells. They studied 6 compounds, with this many study pages each: Thymosin Alpha-1 2, Melanotan II 2, 5-Amino-1MQ 2, Epitalon 1, Retatrutide 1 and Fragment 176-191 1.

What the research on cancer looks like

Read the design before any result. Of these 9 studies, 2 were done on cells in a dish, 3 were in animals and 4 were in people, the largest with 400 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.

Cancer is many diseases, and most of the peptide research tied to it is early: tumor cells grown in a dish and tumors grown in mice. The studies in people here are small trials in which a peptide was added to standard cancer care, and one case report of a harm. None of these studies shows a peptide on its own shrinking a cancer in a person.

Cell studies measure how fast cancer cells grow or die in a dish. Mouse studies measure tumor size and how often tumors take hold. Trials in people measure the response to the whole regimen, infections after surgery and survival.

A peptide that kills cancer cells in a dish or slows tumors in mice has many steps ahead before any test in people, and most such findings never reach one. A case report describes one person and shows a possible risk, not a rate.

Our study pages on cancer by design: Trials in people 1, Other in people 3, Animals 3, Cells 2, of 9.Trials in people1Other in people3Animals3Cells2
How many of the 9 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.

The 9 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Thymosin Alpha-1

    2 in people

    For cancer, 2 of our study pages are filed under Thymosin Alpha-1: 1 randomized trial and 1 clinical trial in people. The largest in people enrolled 400 people and was published in 2024. They were published from 2024 to 2026, in Biotechnol Genet Eng Rev and BMC Med.

    Thymosin alpha-1 (thymalfasin) has no FDA-approved product: Drugs@FDA lists no application for it.

  2. Melanotan II

    2 in people

    For cancer, 2 of our study pages are filed under Melanotan II: 2 observational studies in people. Its studies in people do not give their size on our pages. They were published from 2014 to 2025, in Int J Oral Maxillofac Surg and Dermatology.

    Melanotan II has no FDA-approved product: Drugs@FDA lists no application for it.

  3. 5-Amino-1MQ

    1 in animals · 1 in cells

    For cancer, 2 of our study pages are filed under 5-Amino-1MQ: 1 animal study and 1 cell study (mice and HeLa cervical cancer cells). None of them is in people. They were published from 2021 to 2024, in J Immunother Cancer and J Obstet Gynaecol.

    5-amino-1MQ has no FDA-approved product: Drugs@FDA lists no application for it.

  4. Epitalon

    1 in animals

    For cancer, 1 of our study pages is filed under Epitalon: 1 animal study (rats). It was published in 2002, in Cancer Lett.

    Epitalon has no FDA-approved product: Drugs@FDA lists no application for it.

  5. Retatrutide

    1 in animals

    For cancer, 1 of our study pages is filed under Retatrutide: 1 animal study (mice). It was published in 2025, in NPJ Metab Health Dis.

    Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  6. For cancer, 1 of our study pages is filed under Fragment 176-191: 1 cell study (human MCF-7 breast cancer cells). It was published in 2022, in Drug Des Devel Ther.

    Fragment 176-191 (hGH 176-191) has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 6 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Thymosin Alpha-120400Not approved
Melanotan II20—Not approved
5-Amino-1MQ02—Not approved
Epitalon01—Not approved
Retatrutide01—Not approved
Fragment 176-19101—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for cancer?

Our 9 study pages on cancer are filed under 6 compounds, with this many each: Thymosin Alpha-1 2, Melanotan II 2, 5-Amino-1MQ 2, Epitalon 1, Retatrutide 1 and Fragment 176-191 1. Thymosin Alpha-1, Melanotan II and 5-Amino-1MQ have the most, 2 each.

Have any been tested in people with cancer?

Yes: 4 of the 9 were in people, 1 of them a meta-analysis or randomized trial (Thymosin Alpha-1). The largest enrolled 400 people: “Thymosin alpha-1 lowered infections after colorectal cancer surgery” (2024).

Is any peptide FDA-approved for cancer?

Not by the labels our status pages read: of the 6 compounds here with an FDA record, none has a use tied to cancer.

How large were the studies in people on cancer?

Of the 4 in people, 2 give their size on our pages: 1 had 100 to 999 and 1 had fewer than 100. The largest, a randomized trial from 2024, enrolled 400.

What did the animal and cell studies on cancer use?

3 animal studies (mice and rats) and 2 cell studies (human MCF-7 breast cancer cells and HeLa cervical cancer cells), filed under Retatrutide, 5-Amino-1MQ, Epitalon and Fragment 176-191. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on cancer here?

Of our study pages on cancer, the newest is “Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgery”, a clinical trial in people published in 2026.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.